Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDoris K. HansenLPLauren C. PeresDDDanai Dima

Discussion

Loading...

Member takes

Overview

Multicenter study identifies risk factors for early relapse post-ciltacabtagene autoleucel in multiple myeloma, suggesting tailored consolidation strategies.

Key Points

  • To identify predictors of early relapse following ciltacabtagene autoleucel in relapsed/refractory multiple myeloma patients.
  • Conducted a multi-center study across 15 U.S. academic centers.
  • Evaluated high-risk features associated with progression-free survival.
  • Used multivariable Cox regression to assess associations with early relapse.
  • 33% of patients exhibited functional high-risk disease, correlating with lower overall response rates.
  • FHR and adapted IMS-IMWG HR were independently associated with increased relapse risk within 18 months.
  • Patients without high-risk features showed significantly higher overall response and complete response rates.

Cite This Study

Hansen et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d04ehttps://doi.org/10.1182/blood-2025-93
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma2026
  2. 2Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms.2026 · 1 citations
  3. 3Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality2025 · 7 citations
  4. 4Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis2026 · 3 citations
  5. 5Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.2024 · 14 citations